Nestlé to Acquire Aimmune Therapeutics
Nestlé Health Science (NHSc) has entered into a definitive agreement pursuant to acquire a biopharma company commercializing and developing treatments for potentially life-threatening food allergies, Aimmune Therapeutics.
In children aged 4 through 17, to help reduce the frequency and severity of the allergic reaction to peanuts, including anaphylaxis, Aimmune’s Palforzia is the first and only FDA-approved treatment.
With peanut allergy being the most common among food allergies, globally, up to 240 million people suffer from food allergies. For peanut-allergic patients, Palforzia offers a long-sought-after solution other than avoidance.
CEO of Nestlé Health Science, Greg Behar said, “Nestlé’s nutritional science leadership is brought together with one of the most innovative companies in food allergy treatment through this transaction. Jointly, we will be able to help better the lives of people suffering from food allergies around the world by offering a wide range of solutions.”
MD, President, and CEO of Aimmune, Jayson Dallas said, “A game-changing proposition in the biopharma industry has been delivering the world’s first treatment for food allergy, Palforzia and for the lives of millions of people living with potentially life-threatening peanut allergy, this has been transformative. A level of support for Palforzia is
ensured through this acquisition, which an extension of NHSc’s food allergy portfolio and further, for patients around the world living with food allergies, our pipeline will enhance their potential.”Currently, NHSc has approximately 25.6 percent equity ownership stake, a total of $473 million investment in Aimmune. NHSc has added an investment of $200 million in January 2020, $98 million in November 2018, $30 million in February 2018, after its initial investment of $145 million in Aimmune in November 2016.
The transaction, planned to finance with cash on hand by Nestlé, is anticipated to close in the fourth quarter of 2020, subject to the waiver or satisfaction of customary closing conditions.
Source
Nestlé to Acquire Aimmune Therapeutics, a Biopharma Company located in California
